Skip to main content

New Products

  • Mayo Clinic, health start-up partner for Personal Health Assistant service

    PALO ALTO, Calif. and ROCHESTER, Minn. — Better, a consumer health start-up, and Mayo Clinic have launched a new way for people to navigate the healthcare system. 

    Through a mobile device, Better provides tailored Mayo Clinic health information to the clinic's nurses, and a Better Personal Health Assistant who helps simplify and manage people's care.

  • BIC introduces large-pack offerings of Flex 3, Hybrid Advance 3 razors

    SHELTON, Conn. — BIC, a manufacturer of men’s razors, has developed two new large-pack offerings of the BIC Flex 3 and the BIC Hybrid Advance 3 razors.
     
    The BIC Flex 3 large pack includes eight disposable razors that have three flexible blades and a heavy handle for added control.
     

  • Dr. Reddy's launches eszopiclone tablets

    HYDERABAD, India — Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

    The Lunesta tablets brand and generic combined had sales in the United States of approximately $887 million for the most recent twelve months ending in January 2014, according to IMS Health. Dr. Reddy's eszopiclone tablets 1-mg is available in bottle counts of 30; 2-mg and 3-mg tablets are available in bottle counts of 100.

  • Polaner All Fruit relaunches line of fruit spreads

    PARSIPPANY, N.J. — Polaner All Fruit, a brand from B&G Foods, announced that it is now Non-GMO Project Verified. To recognize its new verification, the company is reviving the "Don't Dare Call it Jelly!" campaign, complete with an interactive digital initiative which encourages consumers to vote for their favorite commercial.

  • Kimberly Clark launches Poise Microliners

    DALLAS — Kimberly Clark on Wednesday announced the launch of the thin and absorbent Poise Microliners, featuring SAM (Super Absorbent Material).

  • FDA sets advisory committee meeting for potential switch of Merck's Singulair Allergy tablets

    SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets. 

    The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older. 

  • Merck's Grastek receives FDA approval

    WHITEHOUSE STATION, N.J. — Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use. The drug is an allergen extract used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is approved for use in persons ages 5 years through 65 years of age.

  • Greenstone announces generic Caduet

    PEAPACK, N.J. — Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products. The drug is the authorized generic versions of Caduet.

X
This ad will auto-close in 10 seconds